ter 286 has been researched along with Local Neoplasm Recurrence in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boulos, L; Brown, GL; Brown, J; Dombroski, JA; Gomez, RF; Henner, WD; Keck, JG; Laxa, B; Lum, RT; Maack, CA; Mascavage, JC; Reiswig, L; Rosen, LS; Schow, SR | 1 |
1 review(s) available for ter 286 and Local Neoplasm Recurrence
Article | Year |
---|---|
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
1 trial(s) available for ter 286 and Local Neoplasm Recurrence
Article | Year |
---|---|
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.
Topics: Adult; Aged; Cytotoxins; Dose-Response Relationship, Drug; Female; Glutathione; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms | 2003 |